Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia.
This study investigated the effects of colesevelam hydrochloride (WelChol; Sankyo Pharma, Parsippany, NJ) and ezetimibe (Zetia; Merck/Schering Plough Pharmaceuticals, North Wales, PA), alone and in combination, for the treatment of hypercholesterolemia in patients who were intolerant to, or refused, HMG-Co-A reductase inhibitor (statin) therapy. Combination therapy with colesevelam HCl/ezetimibe resulted in an additional reduction in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) levels of approximately 20% (P < 0.005) and 16% (P < 0.01), respectively, compared with monotherapy with either agent. Total cholesterol, LDL-C, and non-HDL-C levels were within National Cholesterol Education Program Adult Treatment Panel III target ranges at the end of the combination therapy regimen in 10 of 12 patients. In conclusion, colesevelam HCl/ezetimibe combination therapy appears to be an efficacious and well-tolerated alternative for patients with hypercholesterolemia.